283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era

Background

Prostate cancer is a type of cancer that occurs quite a lot in Indonesia, In 2020, prostate cancer ranks as the 11th most common cancer with 13,563 new cases (3.4%) and the 13th leading cause of death with 4,863 deaths (2.1%). Radiotherapy can be given in low, intermediate, high, and even metastatic states. However, The treatment of choice is influenced by several things, such as risk classification, performance status, patient choice, life expectancy, and access to radiotherapy services.The first step in providing access to radiotherapy services is to calculate the level of need for radiotherapy services.

Methods

The design of this study is cross-sectional, using secondary data on prostate cancer patients from cancer registration in 2019. Data collection starts in October 2022 and ends in January 2023. The 2019 data was chosen because it better describes the normal conditions during the pre-pandemic era. The collected data was identity, age, address, and data related to risk stratification and therapy. The optimal Radiotherapy Utilization Rate (oRUR) calculation method adopts the Collaboration for Cancer Outcomes Research and Evaluation (CCORE), which uses evidence-based guideline modeling methods.

Results

Using a decision tree (CCORE), the range of optimal RUR is 75.3% (66.7–78.3), and the actual RUR is 20.3%. The percentage of unmet need for prostate cancer at RSCM was 73.43% (69.5–74.07). In addition to radiotherapy, as many as 19 (14.3%) patients received chemotherapy treatment, 10 (8%) patients received surgical treatment, 42 (31.6%) patients received hormonal therapy, and 1 (0.8%) patient received samarium therapy.

Conclusions

This considerable difference between oRUR and aRUR can be caused by several things, such as a decrease in referrals to radiotherapy, inadequate and uneven access, fear and anxiety about radiation, adherence to National guidelines, and a limited number of radiotherapy service centers capable of providing radiation with the IMRT technique.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.